Publikationen, an denen er mitarbeitet Sandra Muntión Olave (6)

2024

  1. Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia

    Biomarker Research

2019

  1. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

    British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104

2017

  1. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: A new therapeutic target?

    Oncotarget, Vol. 8, Núm. 17, pp. 28187-28202

  2. Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis

    PLoS ONE, Vol. 12, Núm. 8

2016

  1. MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry

    Cell Communication and Signaling, Vol. 14, Núm. 1

2015

  1. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles

    Leukemia Research, Vol. 39, Núm. 8, pp. 921-924